ReviewJournal of functional biomaterials2021
Quantum Dots: Synthesis, Antibody Conjugation, and HER2-Receptor Targeting for Breast Cancer Therapy.
Review in Journal of functional biomaterials, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 68 citations in OpenAlex.
- Quantum Dot-Based Fluorometric Sensors for Detection of Bacteria: Recent Advances and Emerging Trends.Applied biochemistry and biotechnology · 2026Review
- Preparation of Bimodal Nanoprobes for Fluorescent and Magnetic Resonance Imaging by Conjugating Gadolinium Complexes to Quantum Dots.Methods in molecular biology (Clifton, N.J.) · 2026Article
- The Potential of Next-generation Multi-functional Nanoplatforms for Breast Cancer.Anti-cancer agents in medicinal chemistry · 2026Review
- Quantum Dots: Catalysts for a New Era of Precision Medicine and Biomedical Innovation.Journal of fluorescence · 2026Review
- Sustainable carbon quantum dots synthesized from yeast β-glucan as a promising nanomaterial for biological applications.Scientific reports · 2025Article
- Bioinspired quantum dots: advancing diagnostic and therapeutic strategies in breast cancer.RSC advances · 2025Review
- Surfactant-Enabled Nanocarriers in Breast Cancer Therapy: Targeted Delivery and Multidrug Resistance Reversal.Pharmaceutics · 2025Review
- Zinc Oxide Nanoparticles in Modern Science and Technology: Multifunctional Roles in Healthcare, Environmental Remediation, and Industry.Nanomaterials (Basel, Switzerland) · 2025Review
- Nanocarriers for cutting-edge cancer immunotherapies.Journal of translational medicine · 2025Review
- Chemically synthesized CdSe quantum dots induce apoptosis in AGS gastric cancer cellsNanoscale advances · 2025Article
- Recent innovations in nanomedicine and nano-based techniques for the treatment of breast cancer.BioImpacts : BI · 2025Review
- Mesoporous silica nanoparticles--based functional platforms for breast cancer therapy: technological advancements.Frontiers in chemistry · 2025Review
- Applicability of Quantum Dots in Breast Cancer Diagnostic and Therapeutic Modalities-A State-of-the-Art Review.Nanomaterials (Basel, Switzerland) · 2024Review
- Evaluating a targeted Palbociclib-Trastuzumab loaded smart niosome platform for treating HER2 positive breast cancer cells.International journal of pharmaceutics: X · 2024Article
- Quantum Dot Research in Breast Cancer: Challenges and Prospects.Materials (Basel, Switzerland) · 2024Review
- Advances and prospects of precision nanomedicine in personalized tumor theranostics.Frontiers in cell and developmental biology · 2024Review
- Biosynthesis of Quantum Dots and Their Therapeutic Applications in the Diagnosis and Treatment of Cancer and SARS-CoV-2.Advanced pharmaceutical bulletin · 2023Review
- The potential role of nanomedicine in the treatment of breast cancer to overcome the obstacles of current therapies.Frontiers in pharmacology · 2023Review
- Exploring the potential and safety of quantum dots in allergy diagnostics.Microsystems & nanoengineering · 2023Review
- Optical diagnostic imaging and therapy for thyroid cancer.Materials today. Bio · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is becoming one of the main lethal carcinomas in the recent era, and its occurrence rate is increasing day by day. There are different breast cancer biomarkers, and their overexpression takes place in the metastasis of cancer cells. The most prevalent breast cancer biomarker is the human epidermal growth factor receptor2 (HER2). As this biomarker is overexpressed in malignant breast tissues, it has become the main focus in targeted therapies to fight breast cancer. There is a cascade of mechanisms involved in metastasis and cell proliferation in cancer cells. Nanotechnology has become extremely advanced in targeting and imaging cancerous cells. Quantum dots (QDs) are semiconductor NPs, and they are used for bioimaging, biolabeling, and biosensing. They are synthesized by different approaches such as top-down, bottom-up, and synthetic methods. Fully human monoclonal antibodies synthesized using transgenic mice having human immunoglobulin are used to target malignant cells. For the HER2 receptor, herceptin
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.